| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Oct 6, 2021Late-breaking data demonstrate superior rates of primary patency and statistically significant sustained clinical improvement
Today, Boston Scientific Corporation (NYSE: BSX) announced positive data for the Eluvia™ Drug-Eluting Vascular Stent System (Eluvia stent) during a late-breaking clinical trial presentation at...
-
Oct 5, 2021Two-year data demonstrate continued high rates of primary patency including in patients with complex lesions
Today, Boston Scientific (NYSE: BSX) announced positive results for the Ranger™ Drug-Coated Balloon (DCB) during a late-breaking clinical trial presentation at the Vascular InterVentional...
-
Sep 20, 2021EPOCH trial represents the first positive phase 3 study for selective internal radiation therapy
MARLBOROUGH, Mass. (September 20, 2021) – Boston Scientific Corporation (NYSE: BSX) announced the EPOCH clinical trial of the TheraSphere™ Y-90 Glass Microspheres (TheraSphere treatment)...
-
Jan 22, 2019
Boston Scientific today announced diabetic subanalysis results from the IMPERIAL trial in which patients treated with the ELUVIA™ Drug-Eluting Vascular Stent System demonstrated statistically...
-
Apr 25, 2017Boston Scientific today announced results from the RANGER SFA trial for the Ranger™ Paclitaxel-Coated PTA Balloon Catheter at the Charing Cross Symposium, in London. Data demonstrated that the drug-coated balloon (DCB) exhibited both a high rate of primary patency and freedom from target lesion revascularization (TLR) at 12 months, reducing the need for re-interventions to re-establish flow in previously blocked blood vessels.
The prospective, randomized, controlled trial, comparing the Ranger DCB to uncoated PTA balloons, included 105 patients with femoropopliteal lesions, at ten centers in Europe. Results demonstrate...